Results 251 to 260 of about 77,778 (298)

Health economics and RSV

Paediatric Respiratory Reviews, 2009
An economic analysis was performed in Spain to evaluate the efficiency (cost-effectiveness) of palivizumab in preventing severe RSV infection in premature infants with GA 32-35 and two or more risk factors (RF). The design was a decision tree model using data from the scientific literature and the FLIP I and FLIP II studies IRIS Study Group.
Xavier, Carbonell-Estrany, Pablo, Lázaro y de Mercado   +1 more
openaire   +2 more sources

DSCG Reduces RSV‐induced illness in RSV‐infected mice

Journal of Medical Virology, 2008
AbstractRespiratory syncytial virus (RSV) is one of the pathogens generally associated with the common cold, lower respiratory infection, and exacerbation of asthma. Disodium cromoglycate (DSCG) is a safe and widely used drug for the prevention of bronchial asthma and allergic rhinitis attacks.
Koichi, Hashimoto, Syuichi, Mori, Yuko, Hashimoto, Hisatoshi, Kaneko, Kei, Ishibashi, Ken, Ishioka, Yukihiko, Kawasaki, Ray Stokes, Peebles, Mitsuru, Munakata, Mitsuaki, Hosoya, Tatsuo, Suzutani   +10 more
openaire   +2 more sources

Treating RSV in the immunocompromised

Nursing Standard, 1993
Tribavirin may be a useful treatment for respiratory syncytial virus (RSV) in people who are immunocompromised.
openaire   +2 more sources

Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants

Pediatrics
BACKGROUND AND OBJECTIVES Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract disease (LRTD) in infants and young children. In 2023, the Advisory Committee on Immunization Practices recommended nirsevimab for US infants to prevent ...
Amber, Hsiao, John, Hansen, Bruce, Fireman, Julius, Timbol, Ousseny, Zerbo, Karine, Mari, Christopher, Rizzo, William, La Via, Ruvim, Izikson, Nicola P, Klein   +9 more
openaire   +2 more sources

RSV-Protect

2021
Respiratory syncytial virus (RSV) causes severe respiratory tract infections in infants and elderly. Without antiviral therapies there is an urgent need for a RSV vaccine. Based on an exploratory study in non-human primates (NHP) and the importance of tissue-resident memory T cells for rapid mucosal immune responses the project aims to confirm the ...
openaire   +1 more source

RSV

2023
Markus Knuf, Bernd Salzberger
openaire   +1 more source

Sixty seconds on . . . RSV

BMJ, 2022
openaire   +2 more sources

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

Journal of Infectious Diseases, 2022
Matthieu Beuvelet, Aditya Sardesai, Robert Musci   +2 more
exaly  

Evaluating an RSV inhibitor

Nature Reviews Microbiology, 2022
openaire   +2 more sources

International changes in respiratory syncytial virus (RSV) epidemiology during the COVID‐19 pandemic: Association with school closures

Influenza and Other Respiratory Viruses, 2022
Marie-Noëlle Billard, Peter M Van De Ven, Leyla Kragten-Tabatabaie   +2 more
exaly